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 To the Editor: 
Deferasirox dispersible tablets (DT), a once-daily, oral iron chelator, was approved by the 
US Food and Drug Administration in 2005. Deferasirox DT is typically dispersed in water or 
juice (20–30 mg/kg/day) and taken on an empty stomach ≥30 minutes before a meal.1 For 
patients to receive the maximum therapeutic benefit from chelation therapy, adherence to 
the prescribed dosing regimen is essential. Treatment satisfaction can affect adherence 
and, thus, its ultimate effectiveness.2 Deferasirox DT has been associated with better 
patient satisfaction and adherence (>80%), as well as lower impact on daily activities, than 
the previous standard iron chelator, deferoxamine.3,4 However, barriers to optimal 
adherence exist, including the need to take medication on an empty stomach, palatability, 
and gastrointestinal (GI)-related side effects.  
ECLIPSE was a 24-week, open-label, randomized study (NCT02125877) of DT and a new 
film-coated tablet (FCT) formulation of deferasirox (which can be taken with a light meal) 
among 173 iron chelation-naïve and -experienced patients with transfusion-dependent 
thalassaemia or myelodysplastic syndromes.5 ECLIPSE showed that the safety profile of 
the two formulations were comparable, with FCT recipients experiencing fewer severe GI-
related adverse events (AEs). Although not a study endpoint, serum ferritin was monitored 
to guide dosing. FCT patients had a higher median reduction in serum ferritin from baseline 
(–350.0 [FCT] vs. –85.5 ng/mL [DT]) to study end, suggesting a possible association 
between deferasirox formulation and observed efficacy. Furthermore, FCT patients had 
more favorable patient-reported outcomes (PROs) than DT recipients, reporting better 
adherence, satisfaction, and palatability, and fewer concerns about iron chelation therapy, 
as assessed using modified Satisfaction with Iron Chelation Therapy and palatability 
questionnaires. One explanatory factor of the observed difference in serum ferritin reduction 
could be better treatment adherence among FCT patients. The objective of this post-hoc 
analysis was to estimate the proportion of the observed difference in serum ferritin reduction 
between the two formulations mediated by PROs, with a focus on patient-reported 
 
This article is protected by copyright. All rights reserved.
 adherence. We assessed the proportion mediated (PM) by PROs in the overall population, 
as well as in subgroups with prior DT use (‘DT non-naïve’), with thalassemia only, and in DT 
non-naïve patients with thalassaemia. 
The mediation analysis was based on a method outlined previously.6 Average PROs were 
calculated by taking the average of all available PRO domain scores over the treatment 
period for each patient. Three mediation frameworks with incremental increases in the 
number of mediators were considered: (1) average PRO adherence domain score; (2) all 
average PRO domain scores (adherence, satisfaction, concerns, palatability); and (3) all 
average PRO scores and frequency of severe GI-related AEs (Supplementary Fig S1).  
Univariate and multivariate generalized linear models, with and without the mediator 
variables of interest as predictors, were used to model the association between treatment 
(FCT or DT) and change in serum ferritin from baseline to end of treatment. The multivariate 
models included the covariates age, sex, race, underlying disease, prior use of iron 
chelation therapy, level of iron overload severity at baseline, average planned dose, and 
number of blood transfusions while on treatment. The models without the mediator(s) of 
interest provided an estimate of the total association between treatment and change in 
serum ferritin, ie the association both through and not through the mediator(s). The models 
with the mediator(s) of interest provided an estimate of the association between treatment 
and serum ferritin change not through the mediator(s). Results are reported as PM, ie the 
proportion of the total association between exposure and outcomes that is operationalized 
through the mediator(s) of interest, calculated as one minus the ratio of the association that 
does not go through the mediator, divided by the total association. Analytical variables were 
log transformed or square-root transformed for normality, as required.  
A total of 154 patients had at least one PRO assessment over the study period and were 
included in the analyses. Among these patients, the average patient-reported adherence 
score mediated 66.6% (P=0.012) of the association between treatment and change in 
serum ferritin (Table 1). Patient-reported adherence, satisfaction, concerns, palatability 
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 scores, and frequency of severe GI-related AEs together mediated 90.1% of the association 
(P=0.014). In DT non-naïve patients, the PM by patient-reported adherence was 62.6% 
(P=0.014), and by patient-reported adherence and other PRO scores was 94.3% (P=0.012). 
In the DT non-naïve with thalassemia and thalassemia subgroups, similar trends were 
observed (Table 1).  
In summary, these analyses found that PRO scores, specifically adherence, represent 
important mediators of the observed difference in serum ferritin reduction between the two 
treatment groups. 
The PM was greatest among patients with prior experience with DT. One explanation, 
supported by a previous comparative analysis of iron chelation therapies,3 is that patients 
with prior experience with DT have a reference frame for comparing the new FCT 
formulation with the standard formulation, and are better able to appreciate attributes of the 
new formulation. 
This analysis is subject to several limitations. During ECLIPSE, a larger proportion of FCT 
patients received a higher-than-recommended dose or were not dose adjusted during 
management of AEs, which could have contributed to the observed serum ferritin 
reduction.5 In addition, serum ferritin levels in the deferasirox FCT arm were higher than in 
the DT arm at baseline (2983 vs. 2485 ng/mL). Furthermore, these results may not be 
generalizable outside the context of ECLIPSE because of the stringent inclusion/exclusion 
criteria. Although multivariate models were used to adjust for baseline covariates, the effect 
estimates between treatment group and serum ferritin reduction should be interpreted as 
associations, and the estimates of mediation by PROs should be interpreted as statistical 
mediation and not necessarily as causal.  
In conclusion, this post-hoc analysis supports the importance of considering PROs in 
determining the efficacy of chelation therapy for iron overload. Owing to its better palatability 
and ease of use, deferasirox FCT may be a superior therapy to DT for some patients with 
iron overload by increasing adherence to therapy.  
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 TABLE LEGEND 
Table 1. Multiple mediators of the effect of treatment group (FCT vs DT) on absolute 





1Models adjusted for age, sex, race, underlying disease, level of iron overload severity at baseline, 
average planned dose and number of blood transfusions while on treatment. 
2PM calculated as the ratio of the indirect effect (effect through the mediator) to the total effect (effect both 
through and not through the mediator). 
3Satisfaction, concerns and palatability scores. 
4PM calculated to be >100%; in instances with multiple mediators, because of the interaction between 
them, the PM may be calculated to be >100%. 
AE, adverse event; DT, dispersible tablet; FCT, film-coated tablet; GI, gastrointestinal; PM, proportion 
mediated; PRO, patient-reported outcome. 
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 Table 1. Multiple mediators of the effect of treatment group (FCT vs DT) on absolute 
change in serum ferritin levels from baseline at the end of treatment, overall and by 
subgroup 
 Overall population DT non-naïve patients Patients with thalassaemia 
DT non-naïve patients  
with thalassaemia 
Mediators 
Unadjusted Adjusted1 Unadjusted Adjusted1 Unadjusted Adjusted1 Unadjusted Adjusted1 
PM2 
(%) P  
PM2 
(%) P  
PM2 
(%) P  
PM2 



















score + other 
PRO scores3  









58.4 0.060 90.1 0.014* –4 – –4 – 36.8 0.1472 69.5 0.074 75.7 0.032* 85.1 0.044* 
*P<0.05. 
1Models adjusted for age, sex, race, underlying disease, level of iron overload severity at baseline, 
average planned dose and number of blood transfusions while on treatment. 
2PM calculated as the ratio of the indirect effect (effect through the mediator) to the total effect (effect both 
through and not through the mediator). 
3Satisfaction, concerns and palatability scores. 
4PM calculated to be >100%; in instances with multiple mediators, because of the interaction between 
them, the PM may be calculated to be >100%. 
AE, adverse event; DT, dispersible tablet; FCT, film-coated tablet; GI, gastrointestinal; PM, proportion 
mediated; PRO, patient-reported outcome.  
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